The reported article is a retrospective, registry-based cohort study by the EBMT Lymphoma Working Group that addresses the role of haematopoietic cell transplantation in patients with relapsed or refractory classical Hodgkin lymphoma. The full objectives, hypotheses, and primary endpoints are not included in the source document excerpt provided here.
According to the bibliographic information, the investigation used a retrospective design drawing on registry data from the European Society for Blood and Marrow Transplantation (EBMT). The study is described as "registry-based," indicating reliance on routinely collected transplant and lymphoma follow-up data submitted to the EBMT database.
The source text available to this summary does not include the analytical methods, inclusion or exclusion criteria, variable definitions, follow-up duration, or statistical approach used by the investigators. Those methodological details were not reported in the provided source snippet.
The title and bibliographic record state that the cohort comprised 19,498 patients recorded in the EBMT registry. Beyond the total cohort size, no patient-level characteristics (for example, age distribution, disease stage at transplant, prior therapies, remission status at transplant, transplant modality such as autologous vs allogeneic, conditioning regimens, or comorbidity indices) are provided in the available source content.
Because patient characteristics, subgroup definitions, and outcome measures were not included in the provided excerpt, no summary of treatment heterogeneity or subgroup findings can be derived from this source alone.
The published article lists a large multinational author group. The lead author is Ali Bazarbachi and coauthors include representatives of the EBMT Lymphoma Working Party and clinical transplant centers across Europe and beyond. Affiliations reported in the source include institutions such as the American University of Beirut, EBMT (Paris), Hospital Clínic of Barcelona, University College London Hospitals, King Hussein Cancer Centre, IRCCS Istituto Clinico Humanitas (Italy), Maria Sklodowska-Curie National Research Institute of Oncology (Poland), King Faisal Specialist Hospital & Research Centre (Saudi Arabia), Royal Marsden Hospital (UK), CHU Bordeaux (France), and multiple other centres.
The full set of author names and institutional addresses appears in the source bibliographic entry, but the excerpt does not include author contributions, corresponding author contact beyond an email address listed for the lead author, or disclosures beyond the mention that a conflict of interest statement section exists on the PubMed page.
These details identify the formal publication for retrieval. The PubMed entry indicates the article is available with an abstract and other standard PubMed metadata, but the content available in the source snapshot for this summary was limited.
The source material supplied here contains title-level information, author and affiliation listings, the journal citation, DOI, and PMID. It does not contain the study abstract text, results, numerical outcomes (such as overall survival, progression-free survival, transplant-related mortality, or complications), nor does it include tables, figures, or the authors' conclusions. Consequently:
Where the source does not provide these elements, this rewritten summary explicitly states that those details were not reported in the provided content and recommends consulting the full article.
This registry-based cohort study from the EBMT Lymphoma Working Group reports on 19,498 patients with relapsed or refractory classical Hodgkin lymphoma who underwent haematopoietic cell transplantation. The bibliographic citation and author list are available in the source, but the abstract text and study results are not included in the supplied content. Clinicians, researchers, and other readers seeking results, subgroup analyses, methodology, and authors' conclusions should retrieve the full Lancet Haematology article (DOI 10.1016/S2352-3026(26)00169-9; PMID 42532066) to review complete methods and outcomes.
The full manuscript and abstract are indexed on PubMed (PMID 42532066) and published in Lancet Haematology (Aug 2026). The DOI provided in the source can be used to access the publisher version of record. The PubMed record also references sections for the abstract and conflict of interest statement, which may provide the missing methodological and outcome details not available in this excerpt.